StemCells, Inc. Reports Positive Interim Data From Spinal Cord Injury Trial
NEWARK, Calif. — StemCells, Inc. today announced that interim six-month data from the first patient cohort in the Company's Phase I/II clinical trial of its proprietary HuCNS-SC(R) product candidate (purified …